The U.S. Food and Drug Administration (FDA) granted priority review to an application from Axsome Therapeutics seeking approval of its oral therapy AXS-05 to treat agitation related to Alzheimer’s disease, and expects to decide by April 30, the company said. Priority review shortens the FDA’s review time to six…
Semaglutide, an anti-diabetic medication, did not slow Alzheimer’s disease progression in two large, placebo-controlled Phase 3 clinical trials sponsored by its developer, Novo Nordisk. As a result, the planned one-year extension period for both will be stopped. The EVOKE (NCT04777396) and…
Health Canada has conditionally approved Leqembi (lecanemab) for certain adults with early Alzheimer’s disease, making it the first treatment approved in Canada that targets an underlying cause of early Alzheimer’s by removing toxic amyloid-beta proteins from the brain. The therapy, co-developed by Eisai and Biogen, was cleared for…
Becoming educated and informed about Alzheimer’s is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your Alzheimer’s journey.
There is no cure for Alzheimer’s yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
